CASE STUDY A 19-year-old Caucasian male presented with petechiae and a platelet count of 4 × 10 9 /L, neutrophils 0.3 × 10 9 /L, hemoglobin 9 g/dL with reticulocyte count of 0.019 × 10 9 Bone marrow aspirate…
Introduction Myeloproliferative neoplasms (MPN) are a heterogeneous group of myeloid stem cell disorders shared by certain clinical and biological similarities, and characterized by clonal myeloproliferation without significant dyserythropoiesis, granulocytic dysplasia, or monocytosis. Primary myelofibrosis (PMF), polycythemia vera (PV), and essential…
Key Concepts Hematopoietic cell transplantation provides a curative therapy for patients with myelodysplastic syndrome. The clonal karyotype is the strongest predictor of posttransplant relapse. The availability of human leukocyte antigen (HLA)-matched related and unrelated donors, HLA-haploidentical donors, and umbilical cord…
Disclosures: FTA has provided consultancy to: Genentech, Astrazeneca, Abbvie, Janssen, Pharmacyclics, Gilead sciences, Kite pharma, Celgene, Karyopharm, MEI Pharma, Verastem, Incyte, Beigene, Johnson and Johnson, Dava Oncology, BMS, Merck, Cardinal Health, ADCT therapeutics, Epizyme. PRG has provided consultancy to: Pharmacyclics…
Introduction Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies with an annual age-adjusted incidence rate of 1.8 per 100,000 people in the United States, with an estimated 5690 new cases and 1580 deaths according to the most…
Introduction Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies with an annual age-adjusted incidence rate of 1.73 per 100,000 people in the United States and with a median age of 14 years. It is estimated that 5690…
Brief Overview of Acute Myeloid Leukemia Acute myeloid leukemia (AML) is a heterogeneous clonal disease of myeloid-stem and progenitor cells resulting from mutations, deletions, and epigenetic alterations in genes associated with cell differentiation, proliferation, and renewal. AML represents roughly 1%…
Introduction Acute myeloid leukemia (AML) is the commonest indication for allogeneic hematopoietic cell transplant (allo-HCT) worldwide with numbers rising since its inception 65 years ago. The majority of patients with AML enter complete (morphologic) remission (CR1) with induction therapy; however,…
Introduction Radiation therapy is an effective treatment for many hematologic malignancies in a variety of contexts. In this chapter, we provide a brief review of the mechanism of external beam radiation, discuss radiobiologic principles that guide radiation response and fractionation,…
Introduction Medications used for hematopoietic cell transplant (HCT) and immune effector cell (IEC) therapies are often complex and carry numerous clinical considerations, including understanding of pharmacokinetic and pharmacodynamic principles, drug-drug interactions, adverse effects, and dose adjustment for organ dysfunction. This…